Abstract: Objective To evaluate the efficacy and safety of Artequick-Piperaquine fixed combination (Artequick-Primaquine) for the treatment offalciparum malaria in Comoros,and to investigate the clinical dosage of Artequick-Primaquine for the treatment of falciparum malaria in Africa.Methods One hundred and fifty-five falciparum malaria patients without complications were enrolled into the trial.Artequick-Primaquine tablets were administrated for adults orally once daily (2 tablets ),2-day regimen,and the total dosage were 4 tablets (including Artemisinin 320 mg,Piperaquine 1 500 mg,Primaquine 16 mg).Artequick-Primaqine granules were used to for patients under 6 years old.Follow-up was carried out for the observation of cure rate,recrudescence rate,mean parasite recrudescence time,mean fever clearance time and side effects for 28 days.Results Clinical symptoms were alleviated quickly after drug administration.The mean parasite clearance time (PCT) and mean fever clearance time (FCT) were 51.0 ±25.9 hrs and 20.8 ± 11.4 hrs,respectively.Patients were well tolerated to Artequick-Primaquine tablets.Only few of them had adverse reaction of nausea,vomiting and dizziness,and these adverse reactions were self-limited. No obvious toxicity was found in the comparison of indicators of hematological tests,biochemical examination before treatment and 7 days after the drug administration.Conclusion Artequick-Primaquine has advantages of high efficacy,quick action,few side effects and short regiment for the treatment offalciparum malaria in Comoros.%[目的]评价青蒿素哌喹片联合伯氨喹治疗科摩罗恶性疟有效性和安全性,验证青篙素哌喹片—伯氨喹治疗非洲恶性疟的有效临床剂量.[方法]共观察了无并发症恶性疟患者155例.成人口服青蒿素哌喹片—伯氨喹片1次/d,2片/次,连续2d,1个疗程共4片(青蒿素320 mg,哌喹1 500 mg,伯氨喹16 mg)；6岁以下儿童使用青蒿素哌喹片—伯氨喹颗粒剂.28 d后观察复燃率、平均原虫清除时间、平均退热时间、副作用等.[结果]服药后患者临床症状快速缓解.平均原虫清除时间(PCT)为(51.0±25.9)h,平均退热时间为(20.8±11.4)h.患者对青蒿素哌喹片—伯氨喹有良好的耐受性.只有少数患者出现恶心、呕吐和头晕等不良反应,副作用发生局限且能自愈.患者用药前及开始用药后的第7天观察血常规、生化检查未见明显毒副作用.[结论]青篙素哌喹片—伯氨喹治疗无并发症恶性疟具有高效、速效、副作用低和疗程短等特点.
展开▼
